Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Yousif Matloub, MD, Lia Gore, MD, Mignon L. Loh, MD, Chin-Hon Pui, MD, Michael J. Hanley, PharmD, PhD, Vickie Lu, PhD, E. Jane Leonard, MSc, Muriel Granier, Andrea Biondi, MD, Lewis B. Silverman, MD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-134724

Published: 2020

Journal Articles

Increased Toxicity Among Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia at U.S. Children's Hospitals

Ajay Gupta, MD, Yousif Matloub, MD, Rahul Damania, MD, MaryAnn O'Riordan, Sanjay P Ahuja, MD

Blood (2017) 130 (Supplement 1): 222.

https://doi.org/10.1182/blood.V130.Suppl_1.222.222

Published: 2017

Journal Articles

Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331

Leonard A. Mattano, MD, Meenakshi Devidas, PhD, Alison M. Friedmann, MD MSC, Elizabeth A. Raetz, MD, Mignon Loh, MD, Patrick Buckley, MD PhD, Michael J. Borowitz, MD PhD, Andrew J. Carroll, PhD, Julie Gastier-Foster, PhD, Nyla A. Heerema, PhD, Nina Kadan-Lottick, MD MSPH, Yousif Matloub, MD, David T Marshall, MD, Linda C. Stork, MD, Brent L. Wood, MD PhD, Naomi J. Winick, MD, Stephen Hunger, MD, William L. Carroll, MD, Kelly Maloney, MD

Blood (2014) 124 (21): 793.

https://doi.org/10.1182/blood.V124.21.793.793

Published: 2014

Journal Articles

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331

Kelly W. Maloney, MD, Meenakshi Devidas, PhD, Leonard A. Mattano, Jr., MD, Alison M. Friedmann, MD, MSC, Patrick Buckley, MD, PhD, Michael J. Borowitz, MD, PhD, Andrew J. Carroll, PhD, Julie M. Gastier-Foster, PhD, Nyla A. Heerema, PhD, Nina Kadan -lottick, Mignon L. Loh, MD, Yousif Matloub, MD, David T. Marshall, MD, Linda C. Stork, MD, Elizabeth A. Raetz, MD, Brent L. Wood, MD, PhD, Naomi J. Winick, MD, Stephen P. Hunger, MD, William L. Carroll, MD

Blood (2013) 122 (21): 837.

https://doi.org/10.1182/blood.V122.21.837.837

Published: 2013

Journal Articles

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Yousif Matloub, Bruce C. Bostrom, Stephen P. Hunger, Linda C. Stork, Anne Angiolillo, Harland Sather, Mei La, Julie M. Gastier-Foster, Nyla A. Heerema, Scott Sailer, Patrick J. Buckley, Blythe Thomson, Catherine Cole, James B. Nachman, Gregory Reaman, Naomi Winick, William L. Carroll, Meenakshi Devidas, Paul S. Gaynon

Blood (2011) 118 (2): 243–251.

https://doi.org/10.1182/blood-2010-12-322909

Published: 2011

Journal Articles

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen Hunger, MD, Anne Angiolillo, MD, Meenakshi Devidas, PhD, Mei La, Nyla A. Heerema, Ph.D., Naomi Winick, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Paul S Gaynon, MD

Blood (2010) 116 (21): 497.

https://doi.org/10.1182/blood.V116.21.497.497

Published: 2010

Journal Articles

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial

Linda C. Stork, Yousif Matloub, Emmett Broxson, Mei La, Rochelle Yanofsky, Harland Sather, Ray Hutchinson, Nyla A. Heerema, April D. Sorrell, Margaret Masterson, Archie Bleyer, Paul S. Gaynon

Blood (2010) 115 (14): 2740–2748.

https://doi.org/10.1182/blood-2009-07-230656

Published: 2010

Journal Articles

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Hanna Jean Khoury, MD, Michael J. Mauro, MD, Yousif Matloub, MD, Tai-Tsang Chen, PhD, Erkut Bahceci, MD, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 1128.

https://doi.org/10.1182/blood.V114.22.1128.1128

Published: 2009

Journal Articles

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Yousif Matloub, MD, Bruce C. Bostrom, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Julie M. Gastier-Foster, PhD, Stephen P Hunger, MD, Harland Sather, PhD, Stephen Linda, William L. Carroll, MD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2009) 114 (22): 320.

https://doi.org/10.1182/blood.V114.22.320.320

Published: 2009

Journal Articles

Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.

C. Michel Zwaan, MD, PhD, Carmelo Rizzari, Vincent H.J. van der Velden, Berna Beverloo, M. L. den Boer, Andre Baruchel, Francoise Mechinaud, Donna Lancaster, Yousif Matloub, Dominique Derreumaux, Rob Pieters, Pamela Kearns

Blood (2008) 112 (11): 3241.

https://doi.org/10.1182/blood.V112.11.3241.3241

Published: 2008

Journal Articles

Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).

Kimmo Porkka, MD, PhD, H. Jean Khoury, Ronald Paquette, Yousif Matloub, David Liu, Ritwik Sinha, Jorge Cortes

Blood (2008) 112 (11): 3242.

https://doi.org/10.1182/blood.V112.11.3242.3242

Published: 2008

Journal Articles

Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations

Martin C Müller, Jorge Cortes, MD, Dong-Wook Kim, MD, PhD, Brian J. Druker, Philipp Erben, MD, Ricardo Pasquini, Timothy P Hughes, MD, Yousif Matloub, Lynn Ploughman, Andreas Hochhaus, MD

Blood (2008) 112 (11): 449.

https://doi.org/10.1182/blood.V112.11.449.449

Published: 2008

Journal Articles

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Neil P. Shah, MD, PhD, Dong-Wook Kim, MD, PhD, Hagop M. Kantarjian, MD, Philippe Rousselot, MD, PhD, Pedro Dorlhiac-Llacer, Jorge Milone, MD, Martin C Müller, MD, Yousif Matloub, Alexandre Lambert, Andreas Hochhaus, MD

Blood (2008) 112 (11): 3225.

https://doi.org/10.1182/blood.V112.11.3225.3225

Published: 2008

Journal Articles

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Michael W.N. Deininger, MD, Michael J. Mauro, Yousif Matloub, Ritwik Sinha, Lynn Ploughman, David Liu, Jerald Radich

Blood (2008) 112 (11): 3236.

https://doi.org/10.1182/blood.V112.11.3236.3236

Published: 2008

Journal Articles

The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase

Jorge Cortes, MD, Michael Mauro, Susan O’Brien, Gautam Borthakur, William Wierda, Yousif Matloub, Ritwik Sinha, David Liu, Hagop Kantarjian

Blood (2008) 112 (11): 4265.

https://doi.org/10.1182/blood.V112.11.4265.4265

Published: 2008

Journal Articles

Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CPCML).

Delong Liu, MD, PhD, Yousif Matloub, Jaydip Mukhopadhyay, David Liu, Stuart L Goldberg

Blood (2008) 112 (11): 2128.

https://doi.org/10.1182/blood.V112.11.2128.2128

Published: 2008

Journal Articles

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Catherine Cole, MD, Blythe Thomson, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Mei K La, Patrick J. Buckley, MD, PhD, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2008) 112 (11): 9.

https://doi.org/10.1182/blood.V112.11.9.9

Published: 2008

Journal Articles

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Yousif Matloub, MD, Paul S. Gaynon, MD, Somasundaram Jayabose, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Stephen Linda, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, Sharon R Pine, PhD

Blood (2008) 112 (11): 701.

https://doi.org/10.1182/blood.V112.11.701.701

Published: 2008

Journal Articles

Outcomes for B-Precursor Patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Paul S. Gaynon, MD, Bruce C. Camitta, MD, Yousif Matloub, MD, Paul L. Martin, MD, Naomi Winick, MD, Nita L. Seibel, MD, W. Paul Bowman, MD, Harland N. Sather, PhD, Meenakshi Devidas, PhD, Stephen Hunger, MD, William L. Carroll, MD

Blood (2007) 110 (11): 847.

https://doi.org/10.1182/blood.V110.11.847.847

Published: 2007

Journal Articles

Cerebrospinal Fluid (CSF) Proteomics in Children with Acute Lymphoblastic Leukemia (ALL).

Robert C. Trueworthy, MD, Linda Stork, MD, Yanping Zhong, MD, Sharon Pine, PhD, Yousif Matloub, MD, Ted Laderas, MS, Shannon McWeeney, PhD, Guang Fan, MD, PhD

Blood (2006) 108 (11): 1834.

https://doi.org/10.1182/blood.V108.11.1834.1834

Published: 2006

NARROW

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Increased Toxicity Among Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia at U.S. Children's Hospitals

Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.

Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).

Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase

Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CPCML).

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Outcomes for B-Precursor Patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Cerebrospinal Fluid (CSF) Proteomics in Children with Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only